Phase 1 Clinical Trial Data Indicate IGC’s THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzheimer’s Patients
Cannabis Law Report
DECEMBER 2, 2021
The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021. Over 70% of these patients face one or more debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021).
Let's personalize your content